Novel Developments in Stem Cell Mobilization

Focus on CXCR4

  • Stefan Fruehauf
  • W. Jens Zeller
  • Gary Calandra

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Basic Science and Experimental Studies on Stem Cell Mobilization

    1. Front Matter
      Pages 1-1
    2. Anne Steen, Mette Marie Rosenkilde
      Pages 23-35
    3. Nadia Harun, Kenneth Bradstock, Linda J. Bendall
      Pages 37-54
    4. Eike C. Buss, Anthony D. Ho
      Pages 55-69
  3. Clinical Studies on Stem Cell Mobilization

    1. Front Matter
      Pages 87-87
    2. David C. Dale, W. Conrad Liles
      Pages 89-101
    3. Amy R. MacKenzie, Matias E. Valsecchi, Neal Flomenberg
      Pages 103-131
    4. Stefan Fruehauf, Anthony D. Ho, Jessie Hanrahan, Frank J. Hsu, John F. DiPersio
      Pages 201-219
    5. Maximilian M. Fresen, Kai Hübel
      Pages 221-234
    6. Roberto M. Lemoli, Alessandra D’ Addio
      Pages 263-276
    7. Catherine H. Roberts, John M. McCarty
      Pages 277-301
    8. Klaus Dembowsky, Barbara Romagnoli, Johann Zimmermann, Eric Chevalier, Christian Ludin, Daniel Obrecht
      Pages 303-332
  4. CXCR4 Antagonists for Treatment of Leukemias and Solid Tumors

    1. Front Matter
      Pages 333-333
    2. George Ansstas, Fazia Mir, Michael P. Rettig, Mark Schroeder, Linda Eissenberg, John F. DiPersio
      Pages 335-349
    3. Anupriya Agarwal, Thomas O’Hare, Michael Deininger
      Pages 351-367
    4. Patricia A. Cronin, H. Paul Redmond
      Pages 387-397
    5. Lauren E. Woodard, Sridhar Nimmagadda
      Pages 399-420
  5. Novel Applications

    1. Front Matter
      Pages 421-421
    2. Andre Larochelle, Cynthia E. Dunbar
      Pages 457-485
  6. Back Matter
    Pages 487-496

About this book


Recently, the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development of effective antagonists. One antagonist, plerixafor, is now clinically approved for stem cell mobilization of lymphoma and myeloma patients. This progress allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoietic cells, i.e. leukemia cells. In preclinical studies, a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown.

CXCR4 antagonists are an exciting new class of compounds which are also used for the mobilization of angiogenic cells or for the treatment of solid tumors. This book provides concise reviews of novel developments, as well as possible future developments on CXCR4.  


CXCR4 Cancer Research Mobilization Plerixafor Stem Cell

Editors and affiliations

  • Stefan Fruehauf
    • 1
  • W. Jens Zeller
    • 2
  • Gary Calandra
    • 3
  1. 1., Zentrum für Tumordiagnostik und –therapiParacelsus-KlinikOsnabrückGermany
  2. 2.Deutsches Krebsforschungszentrum (G360)HeidelbergGermany
  3. 3.PrivateCrescoUSA

Bibliographic information